

Curriculum Vitae & Bibliography - Alberto Servetto

PERSONAL INFORMATIONS

Last name / First name **SERVETTO ALBERTO**
Codice fiscale: SRVLR87M17C129I

Date and place of Birth August 17, 1987 – Castellammare di Stabia (NA) – Italy

Citizenship Italian

Current address Via Marconi, 90. Castellammare di Stabia (Naples) – Italy. ZIP: 80053

Telephone +39 3398137349

E-mail alberto.servetto@unina.it albeservetto@gmail.com

CURRENT POSITION

MEDICAL ONCOLOGIST, PhD

15/Sep/2021 – **Assistant Professor of Oncology (RTD-A)** at Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy

16/Dec/2021 - **Medical Oncologist** at Oncology Unit, Department of Onco-hematology, Imaging diagnostics, morphologic diagnostics and legal medicine at Azienda Ospedaliera Universitaria Federico II, Naples, Italy

EDUCATION AND PREVIOUS POSITIONS

01/Apr/2021 – 10/Sep/2021 **Post-doc at Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.**
Project title: Screening, selection and enrollment of patients in phase I clinical trials.

01/Jan/2018 – 25/Mar/2021 **PhD Course: Advanced Biomedical and Surgical Therapies.**
University of Naples Federico II, Naples, Italy
Thesis: “Nuclear FGFR1 regulates gene transcription and promotes antiestrogen resistance in ER+ breast cancer.
Vote: Excellent

01/Mar/2018 – 28/Feb/2021 **Visiting Research Fellowship** at UT Southwestern Medical Center, Simmons Comprehensive Cancer Center, Arteaga Laboratory (Dallas, Texas, USA). Tutor: Carlos L Arteaga

08/Aug/2013 – 08/Aug/2018 **Residency in Medical Oncology**
University of Naples Federico II, Naples, Italy
Vote: 60/60
Thesis: “FGFR signaling pathway alterations mediate resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer”

15/Sep/2017 – 28/Feb/2018 **Visiting Research Fellowship** at Vanderbilt University Medical Center, Division of Hematology/Oncology, Arteaga Laboratory (Nashville, Tennessee, USA)

14/Sep/2016 – 16/Sep/2016 Participation in the ESMO Translational Research Unit Visit – Wien, Austria

20/Mar/2013 **Bachelor Degree in Medicine and Surgery cum Laude**, University of Naples, Federico II

Thesis: "Effect of NVP-LDE 225, Smo inhibitor, in human cellular models of kidney cancer"

TEACHING EXPERIENCES

- Oct/2021 – **Course of Medical Oncology**
School of Medicine and Surgery, University of Naples Federico II, Naples, Italy
- Dec/2021 – **Course of Medical Oncology**
Course of nursing sciences, University of Naples Federico II, Naples, Italy.
- 22/Apr/2022 **Lesson: "The role of predictive molecular pathology in breast cancer"**
Master in "Methodologies of pathological anatomy for the study of predictive biomarkers of response to therapies". University of Naples Federico II, Naples, Italy.

CLINICAL RESEARCH EXPERIENCE

CLDK378A2301: A phase III multicenter, randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive), stage IIIB or IV, non-squamous NSCLC

A Phase II Randomized Trial Comparing a Combination of Abraxane and Gemcitabine Versus Gemcitabine Alone as First Line Treatment in Locally Advanced Unresectable Pancreatic Cancer. GAP (Gemcitabine Abraxane Pancreas) Trial

GIP-2 Phase III Italian Multicenter Study Comparing the Combination of 5-fluorouracil/Folinic Acid, Oxaliplatin and Irinotecan (Folfoxiri) Versus Gemcitabine as Adjuvant Treatment for Resected Pancreatic Cancer

MM-398-07-02-03 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

X396-CLI-301: Phase 3, Randomized Study Comparing X-396 to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients

AWARDS

AACR Associate Member Award at San Antonio Breast Cancer Symposium (SABCS) 2019.
Abstract title: Fibroblast growth factor receptor 1 associates with promoters genome-wide and regulates gene transcription in ER+/FGFR1-amplified breast cancer: Implications for endocrine resistance.

Bando "**STAR: Sostegno Territoriale Attivita' di Ricerca**" University of Naples Federico II, Naples, Italy. **2017**

Title of the project: MARTE: Meccanismi di Acquisizione di Resistenza alle Terapie Endocrine e agli inibitori di chinasi ciclino-dipendenti nel carcinoma della mammilla esprime il recettore degli estrogeni" (Acquired mechanisms of resistance to cyclin-dependent kinases in estrogen receptor positive breast cancer).

RESEARCH GRANTS

- 02/Jan/2023 - ongoing **My First AIRC Grant (MFAG)**, funded by Associazione Italia per la Ricerca sul Cancro. Title of the project: Exploring chromatin remodeling and transcriptional profiles causing resistance to CDK4/6 inhibitors in ER+ breast cancer

SPEAKER AT CONFERENCES

Servetto A, Kollipara R, Formisano L, Lin A, Lee KM, Sudhan DR, Hanker AB, Chatterjee S, Guerrero-Zotano A, Gonzalez-Ericsson, Mendiratta S, James N, Kittler R, Arteaga CL. FGFR1 associates with gene promoters and regulates gene transcription: Implications for endocrine resistance in ER+/FGFR1-amplified breast cancer. December 9, 2020. Oral presentation. General session San Antonio Breast Cancer Symposium (SABCS) 2020, San Antonio TX, USA.

L'ottimizzazione terapeutica nel percorso della paziente con carcinoma mammario ER+/HER2-: il ruolo degli inibitori di CDK4/6. Virtual Meeting. November 9, 2021.

To K.U.R.E.: Towards the future in Kidney and Urothelial Cancer. State of art and updates. Title of

oral presentation: “The era of immune-checkpoint inhibitors”. December 9, 2021. Naples, Italy.

The Prostate Journey. Ottimizzazione del percorso del paziente con CAP. Un approccio a 360°. Title of oral presentation: “Come cambia la pratica clinica nel trattamento del paziente mHSPC (metastatic Hormone-sensitive Prostate Cancer)”. December 14, 2021. Virtual meeting.

Immunoterapia nei tumori solidi. Quando e come: novità dalla letteratura internazionale. Title of oral presentation: “Focus sul melanoma cutaneo”. January 11, 2022. Virtual meeting.

Immunotherapy in solid cancers: news and future directions. Title of presentation: “Update on the role of immunotherapy in NSCLC and SCLC”. April 7, 2022. Naples, Italy

CBM2022 – Campus Breast Meeting 2022. Title of oral presentation: “ER signaling and ER positive breast cancer”. October 8, 2022. Rome, Italy.

Oncology News 2022. Title of oral presentation: “Le news nella terapia medica del carcinoma metastatico del polmone”. December 2, 2022. Apollosa (BN), Italy.

Updates in treatment of non-oncogene addicted NSCLC. Title of presentation: “Criteria for the choice of first line treatment”. Virtual meeting. December 19, 2022.

The TROP2-directed antibody-drug conjugates for solid tumors. Title of presentation: “Potential role for TROP2 targeting in solid tumors”. Virtual meeting. December 21, 2022.

Strengths and Weaknesses in lung cancer. (Participation as discussant). Naples, Italy. January 26/27, 2023

BRAF and MET mutations in NSCLC. Clinical practice and strategies. (Participation as discussant). Naples, Italy. March 23, 2023

Strategic rooms in NSCLC. (Participation as discussant). Monopoli (BA), Italy. March 24-25, 2023.

Master class in precision medicine. Title of presentation: “Precision medicine in breast cancer”. Rome, Italy. April 4-5, 2023.

Reumatologia Tips and Tricks. Presentation about the role on medical oncologist for the management of patients with osteoporosis. Naples, Italy, June 15, 2023

National Conference of Italian Association of Medical Oncologist (AIOM: Associazione Italiana Oncologia Medica) – Young. Educational session about thoracic cancers. Title of presentation: “Un anno di novità: come cambia l’algoritmo terapeutico (One year of news: changes in the therapeutic algorithm). Perugia, Italy, July 8, 2023

Theoretical-practical course about methodology of clinical research (Promoted by AIOM). Title of the course: From evidence-based instruments to big data: the emerging topics”. Round table: winning a grant: my experience. Naples, Italy, September 21, 2023

1st AIRC Southern Italy Scholars. Title of the presentation: Exploring chromatin remodeling and transcriptional profiles associated with resistance to CDK4/6 inhibitors in ER+ breast cancer. Naples, Italy, November 15, 2023

AIOM Campania Prostate Cancer Academy. Title of the presentation: “The importance of QoL data: how to read and interpret them”. Naples, Italy, November 28, 2023

Update on the role immunotherapy in NSCLC. Scientific coordinator. Naples, Italy, November 30, 2023.

Updates in treatment of non-oncogene addicted NSCLC. Title of presentation: “Criteria for the choice of first line treatment”. Virtual meeting. December 13, 2023.

Oncology News 2023. Title of oral presentation: “News from medical treatments in metastatic lung cancer”. December 14, 2023. Benevento, Italy.

XXXVII meeting of GOIM (Gruppo Oncologico Italia Meridionale – Southern Italy Oncology Group). New proposal in research in the field of lung cancer. Title of oral presentation: Immune

research lung: NSCLC. Bari, Italy, February 28, 2024.

Strengths and Weaknesses in lung cancer 2.0. (Participation as discussant). Naples, Italy. April 12, 2024.

PUBLICATIONS

Lin CC, Chang TC, Wang Y, Guo L, Gao Y, Bikorimana E, Lemoff A, Fang YV, Zhang H, Zhang Y, Ye D, Soria-Bretones I, **Servetto A**, Lee KM, Luo X, Otto JJ, Akamatsu H, Napolitano F, Mani R, Cescon DW, Xu L, Xie Y, Mendell JT, Hanker AB, Arteaga CL. PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer. *Nat Commun.* 2024 Mar 13;15(1):2287. doi: 10.1038/s41467-024-46495-2.

Longo V, Della Corte CM, Russo A, Spinnato F, Ambrosio F, Ronga R, Marchese A, Del Giudice T, Sergi C, Casaluze F, Gilli M, Montrone M, Gristina V, Sforza V, Reale ML, Di Liello R, **Servetto A**, Lipari H, Longhitano C, Vizzini L, Manzo A, Cristofano A, Paoletti L, Nardone A, De Summa S, Perrone A, Bisceglia C, Derosa C, Nardone V, Viscardi G, Galetta D, Vitiello F. Consolidative thoracic radiation therapy for extensive-stage small cell lung cancer in the era of first-line chemioimmunotherapy: preclinical data and a retrospective study in Southern Italy. *Front Immunol.* 2024 Jan 18;14:1289434. doi: 10.3389/fimmu.2023.1289434.

Di Costanzo F, Napolitano F, Salomone F, Amato AR, Alberico G, Migliaccio F, Pecoraro G, Marra A, Crocetto F, Ruffo A, Scagliarini S, Rossetti S, Puglia L, Di Napoli M, Bianco R, **Servetto A**, Formisano L. Analysis of Health-Related Quality of Life Reporting in Phase III RCTs of Advanced Genitourinary Tumors. *Cancers (Basel)* . 2023 Dec 4;15(23):5703. doi: 10.3390/cancers15235703.

Nuccio A, Viscardi G, Salomone F, **Servetto A**, Venanzi FM, Riva ST, Oresti S, Ogliari FR, Viganò M, Bulotta A, Cameron R, Esposito A, Hines J, Bianco R, Reni M, Cascone T, Garassino MC, Torri V, Veronesi G, Cinquini M, Ferrara R. Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies. *Eur J Cancer* . 2023 Dec;195:113404. doi: 10.1016/j.ejca.2023.113404.

Belli S, Pesapane A, **Servetto A**, Esposito D, Napolitano F, Ascione CM, Allotta A, Zambrano N, Marino FZ, Franco R, Troiani T, Formisano L, Bianco R. Combined blockade of mTOR and p21-activated kinases pathways prevents tumour growth in KRAS-mutated colorectal cancer. *Br J Cancer* . 2023 Aug 11. doi: 10.1038/s41416-023-02390-z.

Servetto A, Di Maio M, Salomone F, Napolitano F, Paratore C, Di Costanzo F, Viscardi G, Santaniello A, Formisano L, Bianco R. Analysis of phase III clinical trials in metastatic NSCLC to assess the correlation between QoL results and survival outcomes. *BMC Med.* 2023 Jul 3;21(1):234. doi: 10.1186/s12916-023-02953-0.

Belli S, Esposito D, Allotta A, **Servetto A**, Ciciola P, Pesapane A, Ascione CM, Napolitano F, Di Mauro C, Vigliar E, Iaccarino A, De Angelis C, Bianco R, Formisano L. Pak1 pathway hyperactivation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer. *NPJ Breast Cancer* . 2023 May 31;9(1):48. doi: 10.1038/s41523-023-00556-9.

Ascione CM, Napolitano F, Esposito D, **Servetto A**, Belli S, Santaniello A, Scagliarini S, Crocetto F, Bianco R, Formisano L. Role of FGFR3 in bladder cancer: Treatment landscape and future challenges. *Cancer Treat Rev.* 2023 Feb 28. doi: 10.1016/j.ctrv.2023.102530.

De Falco V, Suarato G, Napolitano R, Argenziano G, Famiglietti V, Amato A, **Servetto A**, Bianco R, Formisano L, Terrano V, Esposito A, Giugliano MC, Ciardiello D, Ciardiello F, Napolitano S, Troiani T. Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: data from two Academic Italian Institutions. *Int J Cancer.* 2023 Feb 8. doi: 10.1002/ijc.34462.

Viscardi G, Vitiello F, **Servetto A**, Gristina V, Pizzutilo EG, Canciello MA, Medusa PM, Salomone F, Di Guida G, Mollica M, Aronne L, Scaramuzzi R, Napolitano F, Battiloro C, Caputo F, Gilli M, Totaro G, Curcio C, Rocco D, Montesarchio V. Moving Immune Checkpoint Inhibitors to Early Non-Small Cell Lung Cancer: A Narrative Review. *Cancers (Basel).* 2022 Nov 25;14(23):5810. doi: 10.3390/cancers14235810.

Salomone F, Di Costanzo F, Pecoraro G, Viscardi G, Viggiano A, Napolitano F, Santaniello A, Formisano L, Bianco R, **Servetto A** (Corresponding author). Health-related quality of life is

- underestimated and underreported in phase III clinical trials in NSCLC. *Lung Cancer* 2022, October 18. DOI:<https://doi.org/10.1016/j.lungcan.2022.10.003>
- Servetto A**, Esposito D, Ferrara R, Signorelli D, Belli S, Napolitano F, Santaniello A, Ciciola P, Formisano L, Bianco R. RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges. *Biochimica et Biophysica Acta - Reviews on Cancer*. 2022 Oct 3;188810. doi: 10.1016/j.bbcan.2022.188810.
- Buonaiuto R, Napolitano F, Parola S, De Placido P, Forestieri V, Pecoraro G, **Servetto A**, Formisano L, Formisano P, Giuliano M, Arpino G, De Placido S, De Angelis C. Insight on the Role of Leptin: A Bridge from Obesity to Breast Cancer. *Biomolecules*. 2022 Sep 29;12(10):1394. doi: 10.3390/biom12101394
- Gonzalez-Ericsson PI, **Servetto A**, Formisano L, Sánchez V, Mayer IA, Arteaga CL, Sanders ME. FGFR1 Antibody Validation and Characterization of FGFR1 Protein Expression in ER+ Breast Cancer. *Appl Immunohistochem Mol Morphol*. 2022 Sep 12. doi: 10.1097/PAI.0000000000001058
- Servetto A**, Santaniello A, Napolitano F, Foschini F, Marciano R, Cascetta P, Amato AR, Augurio MR, Maresca L, De Placido P, De Placido S, Formisano L, Bianco R. FOLFIRINOX or nab-paclitaxel plus gemcitabine treatment in metastatic pancreatic adenocarcinoma: an observational study. *Future Oncology*. 2022 Jul;18(21):2643-2653. doi: 10.2217/fon-2021-1142.
- Lee KM, Lin CC, **Servetto A**, Bae J, Kandagatla V, Ye D, Kim GM, Sudhan DR, Mendiratta S, Gonzalez-Ericsson P, Balko JM, Lee J, Barnes S, Malladi V, Tabrizi S, Reddy SM, Yum S, Chang CW, Hutchinson KE, Yost SE, Yuan Y, Chen ZJ, Fu YX, Hanker AB, Arteaga CL. Epigenetic repression of STING by MYC promotes immune evasion and resistance to immune checkpoint inhibitors in triple negative breast cancer. *Cancer Immunol Res*. 2022 May 13;canimm.0826.2021. doi: 10.1158/2326-6066.CIR-21-0826.
- Servetto A**, Salomone F, Di Costanzo F, Iuliano R, Marandino L, Napolitano F, Santaniello A, De Placido P, De Placido S, Di Maio M, Formisano L, Bianco R. Inadequate health-related quality of life assessment and reporting in phase III clinical trials of immune checkpoint inhibitors in solid cancers: a systematic review. *Crit Rev Oncol Hematol*. 2022 Mar 5;103649. doi: 10.1016/j.critrevonc.2022.103649.
- Servetto A**, Santaniello A, Napolitano F, Foschini F, Marciano R, Mozzillo E, Cascetta P, Amato AR, Augurio MR, Maresca L, De Placido P, De Placido S, Formisano L, Bianco R. Use of FOLFIRINOX or nab-paclitaxel plus gemcitabine for the treatment of locally advanced pancreatic adenocarcinoma: a single institution observational study. *Cancers (Basel)*. 2021 Sep 30;13(19):4939.
- Servetto A**, Formisano L, Arteaga CL. FGFR signaling and endocrine resistance in breast cancer: Challenges for the clinical development of FGFR inhibitors. *Biochim Biophys Acta Rev Cancer*. 2021 Jul 23;1876(2):188595.
- Hanker AB, Brown BP, Meiler J, Marín A, Jayanthan HS, Ye D, Lin CC, Akamatsu H, Lee KM, Chatterjee S, Sudhan DR, **Servetto A**, Brewer MR, Koch JP, Sheehan JH, He J, Lalani AS, Arteaga CL. Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity. *Cancer Cell*. 2021 Aug 9;39(8):1099-1114.e8
- Servetto A**, Kollipara R, Formisano L, Lin CC, Lee KM, Sudhan DR, Gonzalez-Ericsson PI, Chatterjee S, Guerrero-Zotano A, Mendiratta S, Akamatsu H, James N, Bianco R, Hanker AB, Kittler R, Arteaga CL. Nuclear FGFR1 Regulates Gene Transcription and Promotes Antiestrogen Resistance in ER + Breast Cancer. *Clin Cancer Res*. 2021 Aug 1;27(15):4379-4396.
- Servetto A**, Napolitano F, De Angelis C, De Placido P, Giuliano M, Arpino G, De Placido S, Bianco R, Formisano L. A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer. *Crit Rev Oncol Hematol*. 2021 Jan;157:103191.
- Lee KM, Guerrero-Zotano AL, **Servetto A**, Sudhan DR, Lin CC, Formisano L, Jansen VM, González-Ericsson P, Sanders ME, Stricker TP, Raj G, Dean KM, Fiolka R, Cantley LC, Hanker AB, Arteaga CL. Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer. *Nat Commun*. 2020 Oct 30;11(1):5488.
- Foschini F, Napolitano F, **Servetto A**, Marciano R, Mozzillo E, Carratù AC, Santaniello A, De

Placido P, Cascetta P, Butturini G, Frigerio I, Regi P, Silvestris N, Delcuratolo S, Vasile E, Vivaldi C, Bianco C, De Placido S, Formisano L, Bianco R. FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules. *Ther Adv Med Oncol.* 2020 Sep 29;12:1758835920947970.

Formisano L, Napolitano F, Rosa R, D'Amato V, **Servetto A**, Marciano R, De Placido P, Bianco C, Bianco R. Mechanisms of resistance to mTOR inhibitors. *Crit Rev Oncol Hematol.* 2020 Mar;147:102886.

Sudhan DR, Guerrero-Zotano A, Won H, González Ericsson P, **Servetto A**, Huerta-Rosario M, Ye D, Lee KM, Formisano L, Guo Y, Liu Q, Kinch LN, Red Brewer M, Dugger T, Koch J, Wick MJ, Cutler RE Jr, Lalani AS, Bryce R, Auerbach A, Hanker AB, Arteaga CL. Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers. *Cancer Cell.* 2020 Feb 10;37(2):183-199.e5.

Drago J, Formisano L, Juric D, Niemierko A, **Servetto A**, Wander S, Spring L, Vidula N, Peppercorn J, Younger J, Malvarosa G, Yuen M, Sgroi D, Isakoff SJ, Moy B, Ellisen LW, Iafrate J, Arteaga CL, Bardia A. FGFR1 gene amplification mediates endocrine therapy resistance but retains relative TORC sensitivity in metastatic hormone receptor positive (HR+) breast cancer. *Clin Cancer Res.* 2019 Nov 1;25(21):6443-6451

Santaniello A, Napolitano F, **Servetto A**, De Placido P, Silvestris N, Bianco C, Formisano L, Bianco R. Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities. *Cancers (Basel).* 2019 Sep 24;11(10)

Napolitano F, Formisano L, Giardino A, Girelli R, **Servetto A**, Santaniello A, Foschini F, Marciano R, Mozzillo E, Carratu` AC, Cascetta P, De Placido P, De Placido S, Bianco R. Neoadjuvant Treatment in Locally advanced pancreatic cancer (LAPC) patients treated with FOLFIRINOX versus Gemcitabine NabPaclitaxel: a single-center experience and a literature review. *Cancers (Basel).* 2019 Jul 13;11(7)

Formisano L, Lu Y, **Servetto A**, Hanker AB, Jansen VM, Bauer JA, Sudhan DR, Guerrero-Zotano AL, Croessmann S, Guo Y, Gonzalez Ericsson P, Lee KM, Nixon MJ, Schwarz L, Sanders ME, Dugger T, Rocha Cruz M, Behdad A, Cristofanilli M, Bardia A, O'Shaughnessy J, Nagy RJ, Lanman RB, Solovieff N, HE W, Miller M, Su F, Shyr Y, Mayer IA, Balko JM, Arteaga CL. Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. *Nat Commun.* 2019 Mar 26;10(1):1373.

Guerrero-Zotano AL, Stricker TP, Formisano L, Hutchinson KE, Stover DG, Lee KM, Schwarz LJ, Giltane JM2, Estrada MV, Jansen VM, **Servetto A**, Gavilá J, Perez-Fidalgo JA, Lluch A, Llombart-Cussac A, Bayar MA, Michiels S, André F, Arnedos M, Guillem V, Ruiz-Simon A, Arteaga CL. ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors. *Clin Cancer Res.* 2018 Jun 1;24(11):2517-2529.

Marciano R, **Servetto A**, Bianco C, Bianco R. Delayed response to maintenance therapy after first-line chemotherapy in metastatic intrahepatic cholangiocarcinoma: a case report. *J Med Case Rep.* 2017 Sep 26; 11: 273

Mauro CD, Pesapane A, Formisano L, Rosa R, D'Amato V, Ciciola P, **Servetto A**, Marciano R, Orsini RC, Monteleone F, Zambrano N, Fontanini G, Servadio A, Pignataro G, Grumetto L, Lavecchia A, Bruzzese D, Iaccarino A, Troncone G, Veneziani BM, Montuori N, Placido S, Bianco R. Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors. *Sci Rep.* 2017 Aug 24;7(1):9388

Di Mauro C, Rosa R, D'Amato V, Ciciola P, **Servetto A**, Marciano R, Orsini RC, Formisano L, De Falco S, Cicatiello V, Di Bonito M, Cantile M, Collina F, Chambery A, Veneziani BM, De Placido S, Bianco R. Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers. *Br J Cancer.* 2017 May 23;116(11):1425-1435

Raimondo L, D'Amato V, **Servetto A**, Rosa R, Marciano R, Formisano L, Di Mauro C, Clara Orsini R, Cascetta P, Ciciola P, De Maio AP, Di Renzo MF, Cosconati S, Bruno A, Randazzo A, Napolitano F, Montuori N, Veneziani BM, De Placido S, Bianco R. Everolimus induces Met inactivation by disrupting the FKBP12/Met complex. *Oncotarget.* 2016 Jun 28;7(26):40073-40084

Formisano L, D'Amato V, **Servetto A**, Brillante S, Raimondo L, Di Mauro C, Marciano R, Orsini

RC, Cosconati S, Randazzo A, Parsons SJ, Montuori N, Veneziani BM, De Placido S, Rosa R, Bianco R. Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status. *Oncotarget*. 2015 Sep 22;6(28):26090-103

D'Amato C, Rosa R, Marciano R, D'Amato V, Formisano L, Nappi L, Raimondo L, Di Mauro C, **Servetto A**, Fulciniti F, Cipolletta A, Bianco C, Ciardiello F, Veneziani BM, De Placido S, Bianco R. Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells. *Br J Cancer*. 2014 Sep 9;111(6):1168-79

D'Amato V, Rosa R, D'Amato C, Formisano L, Marciano R, Nappi L, Raimondo L, Di Mauro C, **Servetto A**, Fusciello C, Veneziani BM, De Placido S, Bianco R. The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models. *Br J Cancer*. 2014 Jun 10;110(12):2887-95

ABSTRACTS IN CONFERENCES

Servetto A, Salomone F, Napolitano F, Santaniello A, Formisano L, Bianco R. Assessment of QoL results and correlation with survival outcomes in phase III clinical trials in metastatic NSCLC. European Lung Cancer Conference (ELCC) 2023. March 31, 2023. Poster Display Session. Copenhagen, Denmark.

Servetto A, Kollipara R, Formisano L, Lin A, Lee KM, Sudhan DR, Hanker AB, Chatterjee S, Guerrero-Zotano A, Gonzalez-Ericsson, Mendiratta S, James N, Kittler R, Arteaga CL. FGFR1 associates with gene promoters and regulates gene transcription: Implications for endocrine resistance in ER+/FGFR1-amplified breast cancer. December 9, 2020. **Oral presentation**. General session SABCS 2020, San Antonio TX, USA.

Servetto A, Kollipara R, Formisano L, Lee KM, Sudhan DR, Hanker AB, Chatterjee S, Lin A, Mendiratta S, James N, Kittler R, Arteaga CL. FGFR1 associates with promoters genome-wide and regulates gene transcription in ER+/FGFR1-amplified breast cancer: Implications for endocrine resistance. Spotligh Session SABCS 2019, San Antonio, TX, USA

Servetto A, Formisano L, Kollipara R, Sudhan DR, Lee KM, Chatterjee S, Hanker AB, Mendiratta S, Kittler R, Arteaga CL. FGFR1 signaling modulates estrogen-independent ER transcriptional activity in ER+/FGFR1-amplified breast cancer cells. AACR 2019, Atlanta, GE, USA

Servetto A, D'Amato V, Rosa R, Di Mauro C, Orsini RC, Ciciola P, Marciano R, De Placido S, Bianco R. The role of p21 Activated Kinase (PAK) in human ColoRectal Cancer cell lines and resistance to cetuximab. ESMO 2016, Copenhagen. Denmark.

Servetto A, D'Amato V, Rosa R, Di Mauro C, Orsini RC, Ciciola P, Marciano R, De Placido S, Bianco R. Effect of NVP-LDE225, a Smo inhibitor, in human hepatocellular carcinoma cell lines. SIC meeting 2016, Verona, Italy

Servetto A, Raimondo L, Formisano L, Marciano R, Di Mauro C, Rosa R, D'Amato V, Veneziani BM, De Placido S, Bianco R. Effects of Hedgehog signaling inhibition on epithelial-stromal interactions in triple negative breast cancer cells. ESMO 2014, Madrid, Spain.

MEMBERSHIPS

- 10/10/2022 - SIC: Società Italiana di Cancerologia
- 24/06/2022 - AIOM: Associazione Italiana di Oncologia Medica
- 19/11/2018 - AACR: American Association for Cancer Research
- 01/10/2014 - European Society for Medical Oncology (ESMO) – Junior member
- 10/07/2013 - Inscription to Albo Professionale dei Medici Chirurghi di Napoli

ENGLISH LANGUAGE

International English Language Testing System - IELTS ACADEMIC: Overall Band Score = 7;

Naples,
April 20, 2024

A handwritten signature in black ink, appearing to read 'Alberto Servetto', written in a cursive style.